

Neutrophil extracellular traps and thrombosis in COVID-19

Yu Zuo¹, Melanie Zuo², Srilakshmi Yalavarthi¹, Kelsey Gockman¹, Jacqueline A. Madison¹, Hui Shi^{1,3}, Wrenn Woodward⁴, Sean P. Lezak⁴, Njira L. Lugogo⁵, Jason S. Knight^{1‡}, and Yogendra Kanthi^{6,7‡},

‡ Jason S. Knight and Yogendra Kanthi are co-corresponding authors

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

² Division of Geriatric and Palliative Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

³ Division of Rheumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

⁴ Michigan Clinical Research Unit, University of Michigan, Ann Arbor, Michigan, USA

⁵ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

⁶ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

⁷ Division of Cardiology, Ann Arbor Veterans Administration Healthcare System, Ann Arbor, Michigan, USA

Correspondence: Jason S. Knight, MD, PhD Yogendra Kanthi, MD
jsknight@umich.edu ykanthi@umich.edu

Competing interests: The authors have no financial conflicts to disclose.

Twitter handles:

Zuo: @rayzuomd

Knight: @jasonsknight

Kanthi: @yogenkanthi

ESSENTIALS

- Mechanisms contributing to frequent thrombosis in COVID-19 remain unknown
- NETs and neutrophil activation were measured in patients with COVID-19 -associated thrombosis
- Thrombosis in COVID-19 was associated with higher levels of circulating NETs and calprotectin
- Contributions of neutrophils and NETs to thrombosis in COVID-19 warrant urgent investigation

ABSTRACT

Background: Early studies of patients with COVID-19 have demonstrated markedly dysregulated coagulation and a high risk of morbid arterial and venous thrombotic events. While elevated levels of blood neutrophils and neutrophil extracellular traps (NETs) have been described in patients with COVID-19, their potential role in COVID-19-associated thrombosis remains unknown.

Objectives: To elucidate the potential role of hyperactive neutrophils and NET release in COVID-19-associated thrombosis.

Patients/Methods: This is a retrospective, case-control study of patients hospitalized with COVID-19 who developed thrombosis (n=11), as compared with gender- and age-matched COVID-19 patients without clinical thrombosis (n=33). In addition to capturing clinical data, we measured remnants of NETs (cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3) and neutrophil-derived S100A8/A9 (calprotectin) in patient sera.

Results: The majority of patients (9/11) were receiving at least prophylactic doses of heparinoids at the time thrombosis was diagnosed. As compared with controls, patients with COVID-19-associated thrombosis had significantly higher blood levels of markers of NETs (cell-free DNA, myeloperoxidase-DNA complexes, citrullinated histone H3) and neutrophil activation (calprotectin). The thrombosis group also had higher levels of D-dimer, CRP, ferritin, and platelets, but not troponin or neutrophils. Finally, there were strong associations between markers of hyperactive neutrophils (calprotectin and cell-free DNA) and D-dimer.

Conclusion: Elevated levels of neutrophil activation and NET formation in patients hospitalized with COVID-19 are associated with higher risk of morbid thrombotic complications. These observations underscore the need for urgent investigation into the potential relationship between NETs and unrelenting thrombosis in COVID-19.

Keywords: blood coagulation, COVID-19, extracellular traps, neutrophils, venous thrombosis

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (**SARS-CoV-2**) causes the disease known as coronavirus disease 2019 (**COVID-19**). It most commonly presents with influenza-like illness and viral pneumonia, but in its most severe manifestation progresses to acute respiratory distress syndrome (**ARDS**) and multi-organ failure [1]. To date the viral pandemic has resulted in millions of infections worldwide (<https://coronavirus.jhu.edu/map.html>).

In COVID-19, elevated levels of blood neutrophils predict severe respiratory disease and unfavorable outcomes [2, 3]. Neutrophil-derived neutrophil extracellular traps (**NETs**) play a pathogenic role in many thrombo-inflammatory states including sepsis [4, 5], thrombosis [6-8], and respiratory failure [9, 10]. NETs are extracellular webs of chromatin and microbicidal proteins that are an evolutionarily conserved aspect of innate immune host-defense [11]; however, NETs also have potential to initiate and propagate inflammation and thrombosis. NETs deliver a variety of oxidant enzymes to the extracellular space, including myeloperoxidase, NADPH oxidase, and nitric oxide synthase, while also serving as a source of extracellular histones that carry significant cytotoxic potential. NETs drive cardiovascular disease by propagating inflammation in vessel walls [12]. Furthermore, when formed intravascularly, NETs can occlude arteries [13], veins [14], and microscopic vessels [15]. Early studies of COVID-19 suggest a high risk of morbid arterial events [16], and the risk of venous thromboembolism (**VTE**) is increasingly revealing itself as more data become available [17].

Descriptive and mechanistic studies to date that examine COVID-19 pathophysiology have focused on monocytes and lymphocytes more so than neutrophils and their effector products. Our group recently reported high levels of NETs in 50 patients hospitalized with COVID-19 as compared with healthy controls [18]. Here, we describe 11 cases of thrombosis in patients hospitalized with COVID-19 and demonstrate an association with neutrophil hyperactivity and NET release.

METHODS

Human samples for NETs analysis. All 44 patients studied here had a confirmed COVID-19 diagnosis based on FDA-approved DiaSorin Molecular Simplexa COVID-19 Direct real-time RT-PCR assay. Blood was collected into serum separator tubes by a trained hospital phlebotomist. After completion of biochemical testing ordered by the clinician, the remaining serum was stored at 4°C for 4 to 48 hours before it was deemed “discarded” and released to the research laboratory. Serum samples were immediately divided into small aliquots and stored at -80°C until the time of testing. This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409), which waived the requirement for informed consent given the discarded nature of the samples.

Quantification of S100A8/A9 (calprotectin). Calprotectin levels were measured with the Human S100A8/S100A9 Heterodimer DuoSet ELISA (DY8226-05, R&D Systems) according to the manufacturer’s instructions.

Quantification of cell-free DNA. Cell-free DNA was quantified in sera using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, P11496) according to the manufacturer’s instructions.

Quantification of myeloperoxidase-DNA complexes. Myeloperoxidase-DNA complexes were quantified similarly to what has been previously described [19]. This protocol used several reagents from the Cell Death Detection ELISA kit (Roche). First, a high-binding EIA/RIA 96-well plate (Costar) was coated overnight at 4°C with anti-human myeloperoxidase antibody (Bio-Rad 0400-0002), diluted to a concentration of 1 µg/ml in coating buffer (Cell Death kit). The plate was washed two times with wash buffer (0.05% Tween 20 in PBS), and then blocked with 4% bovine serum albumin in PBS (supplemented with 0.05% Tween 20) for 2 hours at room temperature. The plate was again washed five times, before incubating for 90 minutes at room temperature with 10% serum or plasma in the aforementioned blocking buffer (without Tween 20). The plate was washed five times, and then incubated for 90 minutes at room temperature with 10x anti-DNA antibody (HRP-conjugated; from the Cell Death kit) diluted 1:100 in blocking buffer. After five more washes, the plate was developed with 3,3',5,5'-Tetramethylbenzidine (TMB) substrate (Invitrogen) followed by a 2N sulfuric acid stop solution. Absorbance was measured at a wavelength of 450 nm using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). Data were normalized to *in vitro*-prepared NET standards included on every plate, which were quantified based on their DNA content.

Quantification of citrullinated-histone H3. Citrullinated-histone H3 was quantified in sera using the Citrullinated Histone H3 (Clone 11D3) ELISA Kit (Cayman, 501620) according to the manufacturer's instructions.

Statistical analysis. When two groups were present, data were analyzed by Mann-Whitney test. Correlations were tested by Pearson's correlation coefficient. Data analysis was with GraphPad Prism software version 8. Statistical significance was defined as $p < 0.05$.

RESULTS

We identified 11 patients who developed a thrombotic event while admitted for treatment of COVID-19 at a large academic medical center (**Table 1**). The events consisted of three strokes and nine VTE events (**Table 2**). Nine were receiving at least prophylactic doses of heparinoids at the time the event was diagnosed. The other two patients were found to have pulmonary emboli on the day of admission (**Table 2**). Nine of the patients were receiving respiratory support by mechanical ventilation at the time of the event. To date, eight have been discharged from the hospital, two have died, and one remains hospitalized.

To better understand the extent to which patients diagnosed with thrombotic events differed from other patients hospitalized with COVID-19, we identified a matched cohort of 33 patients hospitalized with COVID-19 over the same month (**Table 1**). The control cohort was identical for age and sex. The cohort was similar in terms of comorbidities and ultimate outcome (18% died in the thrombosis group and 21% in the control group). For all 44 patients, we were able to access a blood sample collected during their hospitalization. As it relates to diagnosis of the first thrombotic event for each patient, six blood samples were banked within three days of event diagnosis. Three were banked earlier (5, 7, and 12 days prior to event diagnosis) and two later (both at 6 days). As compared with the control group, patients with a thrombotic event demonstrated significantly higher levels of calprotectin, a marker of neutrophil activation (**Figure 1A**). Similarly, three different markers of NETs (cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3) were also markedly elevated in the thrombosis group as compared with the matched controls (**Figure 1B-D**).

We then turned our attention to other clinical biomarkers that might associate with a thrombotic event. The thrombosis group had higher levels of peak D-dimer (**Figure 2A**), but not troponin (**Figure 2B**). Peak CRP and ferritin were also modestly higher in the thrombosis group (**Figure 2C-2D**). Interestingly, peak neutrophil levels did not differ between groups, but platelets were significantly higher in patients who developed thrombosis (**Figure 2E-F**). Finally, we asked whether there was an association between blood markers of neutrophil activation (such as calprotectin and cell-free DNA) and D-dimer within this cohort of COVID-19 patients (n=44). Despite the small number of patients, there were strong correlations between peak D-dimer and both calprotectin and cell free DNA (**Figure 3A-B**).

DISCUSSION

Hyperactivity of the coagulation system is a common finding of severe COVID-19 [20]. Indeed, many patients have a profile to suggest a prothrombotic diathesis including high levels of fibrin degradation products (D-dimer), elevated fibrinogen levels, and low antithrombin levels [20, 21]. We recently characterized the blood of 50 patients hospitalized with COVID-19 and found significantly elevated levels of NETs as compared with healthy controls [18]. Here, we extend that analysis by demonstrating particularly high levels of NETs in a subgroup of COVID-19 patients diagnosed with a thrombotic event. Given the known link between NETs and thrombosis in many inflammatory conditions, these data suggest that the role of NETs in COVID-19-associated thrombophilia warrants systematic investigation.

Intravascular NET release is responsible for initiation and accretion of thrombotic events in arteries, veins, and microvessels, where thrombotic disease can drive end-organ damage in lungs, heart, kidneys, and other organs[22, 23]. Mechanistically, DNA in NETs may directly activate the extrinsic pathway of coagulation[24], while NETs also present tissue factor to initiate the intrinsic pathway[25]. Serine proteases in NETs such as neutrophil elastase release brakes on coagulation by proteolyzing various tissue factor pathway inhibitors [26]. Bidirectional interplay between NETs and platelets might also be critical for COVID-19-associated thrombosis as has been characterized in a variety of disease models [23, 24].

Approaches to combatting NETs [27-29] include the dismantling of NETs with deoxyribonucleases and strategies that prevent initiation of NET release such as neutrophil elastase inhibitors and peptidylarginine deiminase 4 inhibitors. As we await definitive antiviral and immunologic solutions to the current pandemic, we posit that anti-neutrophil therapies may be part of a personalized strategy for some individuals affected by COVID-19. Furthermore, those patients with hyperactive neutrophils may be at particularly high risk for thrombotic events and might therefore benefit from more aggressive anticoagulation while hospitalized.

ACKNOWLEDGEMENTS

The work was supported by a COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center as well as by the A. Alfred Taubman Medical Research Institute. YZ was supported by career development grants from the Rheumatology Research Foundation and APS ACTION. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Lupus Research Alliance, and Burroughs Wellcome Fund. YK was supported by the NIH (K08HL131993, R01HL150392), Falk Medical Research Trust Catalyst Award, and the JOBST-American Venous Forum Award. The authors also thank all members of the “NETwork to Target Neutrophils in COVID-19” for their helpful advice and encouragement.

AUTHORSHIP

YZ, MZ, SY, KG, JM, HS, WW, and SPL conducted experiments and analyzed data. YZ, MZ, NLL, YK, and JSK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.

REFERENCES

- 1 Pedersen SF, Ho YC. SARS-CoV-2: A Storm is Raging. *J Clin Invest.* 2020. 10.1172/JCI137647.
- 2 Zhang B, Zhou X, Zhu C, Feng F, Qiu Y, Feng J, Jia Q, Song Q, Zhu B, Wang J. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. 2020: 2020.03.12.20035048. 10.1101/2020.03.12.20035048 %J medRxiv.
- 3 Song C-Y, Xu J, He J-Q, Lu Y-Q. COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients. 2020: 2020.03.05.20031906. 10.1101/2020.03.05.20031906 %J medRxiv.
- 4 Iba T, Levy JH, Raj A, Warkentin TE. Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. *J Clin Med.* 2019; **8**. 10.3390/jcm8050728.
- 5 Ward PA, Fattahi F. New strategies for treatment of infectious sepsis. *J Leukoc Biol.* 2019; **106**: 187-92. 10.1002/JLB.4MIR1118-425R.
- 6 Ali RA, Gandhi AA, Meng H, Yalavarthi S, Vreede AP, Estes SK, Palmer OR, Bockenstedt PL, Pinsky DJ, Greve JM, Diaz JA, Kanthi Y, Knight JS. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. *Nat Commun.* 2019; **10**: 1916. 10.1038/s41467-019-09801-x.
- 7 Meng H, Yalavarthi S, Kanthi Y, Mazza LF, Elflin MA, Luke CE, Pinsky DJ, Henke PK, Knight JS. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. *Arthritis Rheumatol.* 2017; **69**: 655-67. 10.1002/art.39938.
- 8 Yadav V, Chi L, Zhao R, Tourdot BE, Yalavarthi S, Jacobs BN, Banka A, Liao H, Koonse S, Anyanwu AC, Visovatti SH, Holinstat MA, Kahlenberg JM, Knight JS, Pinsky DJ, Kanthi Y. Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1beta-driven venous thrombosis. *J Clin Invest.* 2019; **129**: 2872-7. 10.1172/JCI124804.
- 9 Potey PM, Rossi AG, Lucas CD, Dorward DA. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. *J Pathol.* 2019; **247**: 672-85. 10.1002/path.5221.
- 10 Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation. *Respiration.* 2017; **93**: 212-25. 10.1159/000453002.
- 11 Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. *Science.* 2004; **303**: 1532-5. 10.1126/science.1092385.
- 12 Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. *Science.* 2015; **349**: 316-20. 10.1126/science.aaa8064.
- 13 Doring Y, Soehnlein O, Weber C. Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis. *Circ Res.* 2017; **120**: 736-43. 10.1161/CIRCRESAHA.116.309692.
- 14 Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J Thromb Haemost.* 2012; **10**: 136-44. 10.1111/j.1538-7836.2011.04544.x.
- 15 Tanaka K, Koike Y, Shimura T, Okigami M, Ide S, Toiyama Y, Okugawa Y, Inoue Y, Araki T, Uchida K, Mohri Y, Mizoguchi A, Kusunoki M. In vivo characterization of neutrophil extracellular traps in various organs of a murine sepsis model. *PLoS One.* 2014; **9**: e111888. 10.1371/journal.pone.0111888.
- 16 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality

- of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020; **395**: 1054-62. 10.1016/S0140-6736(20)30566-3.
- 17 Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 influenza infection and vascular thrombosis. *Clin Infect Dis*. 2011; **52**: e14-7. 10.1093/cid/ciq125.
- 18 Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair CN, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS. Neutrophil extracellular traps in COVID-19. *JCI Insight*. 2020. 10.1172/jci.insight.138999.
- 19 Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, Grone HJ, Brinkmann V, Jenne DE. Netting neutrophils in autoimmune small-vessel vasculitis. *Nat Med*. 2009; **15**: 623-5. 10.1038/nm.1959 [pii].
- 20 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020; **18**: 844-7. 10.1111/jth.14768.
- 21 Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med*. 2020. 10.1515/cclm-2020-0188.
- 22 Pfeiler S, Massberg S, Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. *Thromb Res*. 2014; **133 Suppl 1**: S35-7. 10.1016/j.thromres.2014.03.016.
- 23 Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. *J Thromb Haemost*. 2008; **6**: 415-20. 10.1111/j.1538-7836.2007.02865.x.
- 24 Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. *Arterioscler Thromb Vasc Biol*. 2014; **34**: 1977-84. 10.1161/ATVBAHA.114.304114.
- 25 Kambas K, Chrysanthopoulou A, Vassilopoulos D, Apostolidou E, Skendros P, Girod A, Arelaki S, Froudarakis M, Nakopoulou L, Giatromanolaki A, Sidiropoulos P, Koffa M, Boumpas DT, Ritis K, Mitroulis I. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. *Ann Rheum Dis*. 2014; **73**: 1854-63. 10.1136/annrheumdis-2013-203430.
- 26 Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med*. 2010; **16**: 887-96. 10.1038/nm.2184.
- 27 Thalín C, Hisada Y, Lundström S, Mackman N, Wallén H. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis. *Arterioscler Thromb Vasc Biol*. 2019; **39**: 1724-38. 10.1161/ATVBAHA.119.312463.
- 28 Barnado A, Crofford LJ, Oates JC. At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. *J Leukoc Biol*. 2016; **99**: 265-78. 10.1189/jlb.5BT0615-234R.
- 29 Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Dassler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med*. 2020; **217**. 10.1084/jem.20200652.

Table 1: COVID-19 patient characteristics		
	Thrombosis (n=11)	Matched (n=33)
Demographics		
Age (years)*	56 ± 12 (38-77)	57 ± 12 (33-82)
Female	2 (18.1%)	6 (18.2%)
White/Caucasian	3 (27.2%)	14 (42.4%)
Black/African-American	5 (45.5%)	15 (45.5%)
Unknown	2 (18.2%)	4 (12.1%)
Thrombosis		
Arterial	2 (18.1%)	0 (0%)
Venous	8 (72.7%)	0 (0%)
Both	1 (9%)	0 (0%)
Comorbidities		
Ischemic heart disease	5 (45.5%)	8 (24.2%)
History of stroke	1 (9%)	4 (12.1%)
Hypertension	6 (54.5%)	22 (66.7%)
Obesity	6 (54.5%)	22 (66.7%)
History of smoking	4 (36.4%)	8 (24.2%)
Diabetes	4 (36.4%)	15 (45.5%)
Renal disease	4 (36.4%)	10 (30.3%)
Lung disease	1 (9%)	6 (18.2%)
Cancer	1 (9%)	6 (18.2%)
Autoimmune disease	1 (9%)	0 (0%)
Immune deficiency	0	4 (12.1%)
Outcome		
Discharged	8 (72.7%)	23 (69.5%)
Death	2 (18.1%)	7 (21.2%)
Remains hospitalized	1 (9%)	3 (9%)
* Mean ± standard deviation		

Table 2: Thrombosis details in patients with COVID-19							
Patient	Age	Sex	Day	Ventilation	Event	Prophylaxis	Outcome
1	70s	F	3	Mechanical	Acute PE	SQ Heparin 5000 U TID	Discharge
2	60s	M	9	Mechanical	Ischemic stroke (left middle cerebral artery)	SQ Heparin 5000 U TID	Discharge
			19	Mechanical	LE DVT (right femoral vein, iliac vein, and popliteal vein)	SQ Heparin 7500 U TID	
3	50s	M	16	Mechanical	Ischemic stroke (left posterior cerebral artery)	SQ Heparin 5000 U TID	Death
4	50s	M	27	Mechanical	Ischemic stroke (both supra- and infra-tentorial foci, suggesting an embolic source)	SQ Heparin 7500 U TID	Remains in hospital
5	30s	M	2	Mechanical	Bilateral LE DVT (right popliteal vein, left gastrocnemius vein)	Enoxaparin 40 mg daily	Discharge
6	40s	M	2	Mechanical	Bilateral LE DVT (bilateral common femoral veins and popliteal veins)	SQ Heparin 5000 U TID	Discharge
7	40s	M	36	Mechanical	Acute PE (segmental and subsegmental)	Heparin gtt 1400 U/hour	Death
8	40s	F	1	Nasal cannula	Acute PE (segmental and subsegmental)	None	Discharge
9	50s	M	1	Room air	Acute PE (segmental and subsegmental)	None	Discharge
10	60s	M	5	Mechanical	UE DVT (right UE DVT)	Enoxaparin 40 mg daily	Discharge
11	70s	M	9	Mechanical	Acute PE (segmental)	Heparin gtt 850 U/hour	Discharge

F=female; M=male; SQ=subcutaneous; gtt=continuous IV heparin; LE=lower extremity; UE=upper extremity; DVT=deep vein thrombosis; PE=pulmonary embolism; u=units; TID=three times daily




Figure 1: Elevated levels of NETs in the blood of COVID-19 patients diagnosed with a thrombotic event, as compared with matched controls. Serum was tested for calprotectin (A), cell-free DNA (B), myeloperoxidase-DNA complexes (C), and citrullinated histone H3 (D). N=33 for the control group and n=11 for the thrombosis group. Comparisons were by Mann-Whitney test; * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.




Figure 2: Association between peak levels of clinical biomarkers and diagnosis of a thrombotic event. Clinical testing is reported for D-dimer (A), troponin (B), C-reactive protein (C), ferritin (D), absolute neutrophil count (E), and absolute platelet count (F). N=33 for the control group and n=11 for the thrombosis group. Comparisons were by Mann-Whitney test; *p<0.05 and **p<0.01. Comparisons for peak troponin and peak neutrophil count were not statistically significant.




Figure 3: Correlation between neutrophil activation markers and D-dimer. Calprotectin (A) and cell-free DNA (B) were compared to peak D-dimer levels. Data were analyzed by Pearson's method.